Literature DB >> 28004856

Effect of early allograft dysfunction on outcomes following liver transplantation.

Jana Hudcova1,2, Caitlin Scopa3, Jawad Rashid4, Ahsan Waqas3, Robin Ruthazer5, Roman Schumann4.   

Abstract

Early allograft dysfunction (EAD) following liver transplantation (LT) remains a challenge for patients and clinicians. We retrospectively analyzed the effect of pre-defined EAD on outcomes in a 10-year cohort of deceased-donor LT recipients with clearly defined exclusion criteria. EAD was defined by at least one of the following: AST or ALT >2000 IU/L within first-week post-LT, total bilirubin ≥10 mg/dL, and/or INR ≥1.6 on post-operative day 7. Ten patients developed primary graft failure and were analyzed separately. EAD occurred in 86 (36%) recipients in a final cohort of 239 patients. In univariate and multivariate analyses, EAD was significantly associated with mechanical ventilation ≥2 days or death on days 0, 1, PACU/SICU stay >2 days or death on days 0-2 and renal failure (RF) at time of hospital discharge (all P<.05). EAD was also significantly associated with higher one-year graft loss in both uni- and multivariate Cox hazard analyses (P=.0203 and .0248, respectively). There was no difference in patient mortality between groups in either of the Cox proportional hazard models. In conclusion, we observed significant effects of EAD on short-term post-LT outcomes and lower graft survival.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  deceased donor; duration of intubation; graft and patient survival; hospital length of stay; multivariate logistic regression; post-transplant renal failure; postoperative recovery; primary graft failure; univariate logistic regression

Mesh:

Year:  2017        PMID: 28004856     DOI: 10.1111/ctr.12887

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  16 in total

1.  Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury.

Authors:  Kojiro Nakamura; Shoichi Kageyama; Fady M Kaldas; Hirofumi Hirao; Takahiro Ito; Kentaro Kadono; Kenneth J Dery; Hidenobu Kojima; David W Gjertson; Rebecca A Sosa; Maciej Kujawski; Ronald W Busuttil; Elaine F Reed; Jerzy W Kupiec-Weglinski
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 2.  The Role of Neutrophils as a Driver in Hepatic Ischemia-Reperfusion Injury and Cancer Growth.

Authors:  Christof Kaltenmeier; Hamza O Yazdani; Sanah Handu; Brandon Popp; David Geller; Samer Tohme
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 3.  Targeting the Hepatic Microenvironment to Improve Ischemia/Reperfusion Injury: New Insights into the Immune and Metabolic Compartments.

Authors:  Fengqiang Gao; Xun Qiu; Kai Wang; Chuxiao Shao; Wenjian Jin; Zhen Zhang; Xiao Xu
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

4.  Liver Ischemia and Reperfusion Induce Periportal Expression of Necroptosis Executor pMLKL Which Is Associated With Early Allograft Dysfunction After Transplantation.

Authors:  Shaojun Shi; Eliano Bonaccorsi-Riani; Ivo Schurink; Thierry van den Bosch; Michael Doukas; Karishma A Lila; Henk P Roest; Daela Xhema; Pierre Gianello; Jeroen de Jonge; Monique M A Verstegen; Luc J W van der Laan
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

5.  Decreasing Significance of Early Allograft Dysfunction with Rising Use of Nonconventional Donors.

Authors:  Stephanie Ohara; Elizabeth Macdonough; Lena Egbert; Abigail Brooks; Blanca Lizaola-Mayo; Amit K Mathur; Bashar Aqel; Kunam S Reddy; Caroline C Jadlowiec
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

6.  The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Authors:  Karen L Thomsen; Francis P Robertson; Peter Holland-Fischer; Brian R Davidson; Rajeshwar P Mookerjee; Holger J Møller; Rajiv Jalan; Henning Grønbæk
Journal:  J Clin Exp Hepatol       Date:  2018-10-05

7.  Study design of the DAS-OLT trial: a randomized controlled trial to evaluate the impact of dexmedetomidine on early allograft dysfunction following liver transplantation.

Authors:  Chenlu Ni; Joe Masters; Ling Zhu; Weifeng Yu; Yingfu Jiao; Yuting Yang; Cui Cui; Suqing Yin; Liqun Yang; Bo Qi; Daqing Ma
Journal:  Trials       Date:  2020-06-26       Impact factor: 2.279

Review 8.  Heme Oxygenase-1 in liver transplant ischemia-reperfusion injury: From bench-to-bedside.

Authors:  Hirofumi Hirao; Kenneth J Dery; Shoichi Kageyama; Kojiro Nakamura; Jerzy W Kupiec-Weglinski
Journal:  Free Radic Biol Med       Date:  2020-02-19       Impact factor: 7.376

9.  Rotational thromboelastometry (ROTEM) 24 hours post liver transplantation predicts early allograft dysfunction.

Authors:  Dana Tomescu; Mihai Popescu; Simona Olimpia Dima
Journal:  Rom J Anaesth Intensive Care       Date:  2018-10

10.  Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation.

Authors:  Hirofumi Hirao; Takahiro Ito; Jerzy W Kupiec-Weglinski; Fady M Kaldas; Kentaro Kadono; Hidenobu Kojima; Bita V Naini; Kojiro Nakamura; Shoichi Kageyama; Ronald W Busuttil
Journal:  Hepatology       Date:  2021-08-30       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.